TABLE 4.
Restrictions on claims completeness for generic and branded warfarin for individuals in the 6-month calendar cohorts containing INR claims
| No. of 6-month cross sections remaining | Percent appearing: Generic (95% CI)* | Percent appearing: Brand (95% CI)* | Percent appearing: Total (95% CI) | |
|---|---|---|---|---|
| Restriction Criterion | ||||
| No Exclusion Criteria | 266,010 | 71.6 (71.4-71.8) | 22.9 (22.6-23.3) | 89.4 (89.2-89.5) |
| ≥ 1 prescription fill | 264,206 | 71.5 (71.3-71.7) | 22.9 (22.6-23.3) | 89.3 (89.2-89.4) |
| Hospitalization | 197,943 | 70.3 (70.1-70.6) | 23.7 (23.3-24.1) | 89.5 (89.3-89.6) |
| Hepatic-related diagnosis | 262,507 | 71.6 (71.4-71.8) | 23.0 (22.6-23.3) | 89.4 (89.2-89.5) |
| Vitamin K deficiency | 262,760 | 71.5 (71.3-71.7) | 23.0 (22.6-23.3) | 89.3 (89.2-89.4) |
| Anti-phospholipid syndrome | 263,821 | 71.5 (71.3-71.7) | 22.9 (22.6-23.3) | 89.3 (89.2-89.4) |
| Other coagulation deficiency | 255,628 | 71.4 (71.2-71.6) | 23.0 (22.6-23.3) | 89.2 (89.1-89.4) |
| Cardiac ablation procedure | 252,295 | 71.4 (71.2-71.6) | 23.0 (22.7-23.4) | 89.3 (89.1-89.4) |
| Outpatient claim for either heparin or LMWH | 245,117 | 70.8 (70.6-71.0) | 22.9 (22.6-23.3) | 88.8 (88.6-88.9) |
| All exclusion criteria | 183,308 | 70.1 (69.9-70.4) | 23.8 (23.4-24.2) | 89.4 (89.2-89.5) |
| All criteria + prescription aspirin use | 182,989 | 70.1 (69.9-70.4) | 23.8 (23.4-24.2) | 89.4 (89.2-89.5) |
*
Columns may add up to more than the total
Abbreviations: INR: international normalized ratio; CI, Confidence interval; LMWH: Low-molecular weight heparin